Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Commissioner Von Eschenbach: NCI Director Named Acting Head Of FDA

This article was originally published in The Tan Sheet

Executive Summary

National Cancer Institute Director Andrew von Eschenbach, MD, brings extensive scientific expertise and experience working with Congress as the head of a high-profile federal agency to the role of FDA commissioner
Advertisement

Related Content

Crawford Pleads Guilty Of Failing To Disclose Stocks In Firms FDA Regulates
Crawford Pleads Guilty Of Failing To Disclose Stocks In Firms FDA Regulates
Crawford Pleads Guilty Of Failing To Disclose Stocks In Firms FDA Regulates
Von Eschenbach Slated For Nomination As Permanent FDA Head
Von Eschenbach Slated For Nomination As Permanent FDA Head
Crawford joins lobbying firm
Acting FDA Head Von Eschenbach Takes A Step Back At NCI
FDAer Resigns Over Plan B; Senators Seek Results Of GAO Investigation
Crawford Nomination Clears OIG Hurdle To Face Committee Vote, Plan B Hold
Crawford Nomination Clears OIG Hurdle To Face Committee Vote, Plan B Hold

Topics

Advertisement
UsernamePublicRestriction

Register

PS098670

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel